[go: up one dir, main page]

AR084234A1 - Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) - Google Patents

Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)

Info

Publication number
AR084234A1
AR084234A1 ARP110104621A ARP110104621A AR084234A1 AR 084234 A1 AR084234 A1 AR 084234A1 AR P110104621 A ARP110104621 A AR P110104621A AR P110104621 A ARP110104621 A AR P110104621A AR 084234 A1 AR084234 A1 AR 084234A1
Authority
AR
Argentina
Prior art keywords
methods
interleuquine
antagonists
predictive
treat arthritis
Prior art date
Application number
ARP110104621A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR084234A1 publication Critical patent/AR084234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente acta se dirige a métodos predictivos y terapias personalizadas para tratar la artritis reumatoide (RA). Específicamente, la presente se relaciona con predecir la probabilidad de que un paciente con artritis reumatoide responderá clínicamente al tratamiento con una molécula de enlace de IL-17, por ejemplo, un anticuerpo de IL-17, tal como secukinumab.
ARP110104621A 2010-12-13 2011-12-12 Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) AR084234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42252110P 2010-12-13 2010-12-13

Publications (1)

Publication Number Publication Date
AR084234A1 true AR084234A1 (es) 2013-05-02

Family

ID=45390221

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104621A AR084234A1 (es) 2010-12-13 2011-12-12 Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)

Country Status (3)

Country Link
AR (1) AR084234A1 (es)
TW (1) TW201307845A (es)
WO (1) WO2012082573A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2566517T (pt) 2010-05-04 2019-01-24 Five Prime Therapeutics Inc Anticorpos que ligam csf1r
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
BR112014012101A2 (pt) * 2011-11-21 2019-09-24 Novartis Ag métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN107759690A (zh) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EA037561B1 (ru) 2014-06-23 2021-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
CN115944734A (zh) 2014-09-10 2023-04-11 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
RS61602B1 (sr) 2014-10-29 2021-04-29 Five Prime Therapeutics Inc Kombinovana terapija za kancer
HK1245804A1 (zh) 2014-12-22 2018-08-31 Five Prime Therapeutics, Inc. 用於治疗pvns的抗csf1r抗体
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN107709365A (zh) 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CA3155108A1 (en) 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR20080099290A (ko) 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 ｉｌ-17 길항 항체
MY153893A (en) * 2008-09-29 2015-04-15 Roche Glycart Ag Antibodies against human il17 and uses thereof

Also Published As

Publication number Publication date
TW201307845A (zh) 2013-02-16
WO2012082573A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
AR084234A1 (es) Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
CY1122978T1 (el) Αντισωματα εναντι-vla-4
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
EA201400254A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EA201300978A1 (ru) Антитела к сеа
CL2013001213A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide.
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
MY163539A (en) Antibody fc variants
EA201500876A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
BR112012006035A2 (pt) epratuzumab para uso no tratamento de uma doença autoimune ou inflamatória, e, kit
MX341884B (es) Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
MX2013009362A (es) Anticuerpo contra el csf-1r.
MX391802B (es) Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
CR20130593A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
EA201400875A1 (ru) Антитела к cd47 и способы их применения
AR061568A1 (es) Compuestos
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
CR20110559A (es) Anticuerpos específicos para cadherina-17
CR20150153A (es) Tratamiento para artitris reumatoide
BR112013032871A8 (pt) Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154
EP4282881A3 (en) Antibodies against csf-1r
PH12013502340A1 (en) Biomarkers for hedgehog inhibitor therapy
WO2012122334A3 (en) Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal